A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532).

Date publication

janvier 2024

Journal

European urology oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr QUIVRIN Magali

Tous les auteurs :
Tombal BF, Gomez-Veiga F, Gomez-Ferrer A, López-Campos F, Ost P, Roumeguere TA, Herrera-Imbroda B, D'Hondt LA, Quivrin M, Gontero P, Villà S, Khaled H, Fournier B, Musoro J, Krzystyniak J, Pretzenbacher Y, Loriot Y

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38272747

Résumé

Darolutamide is an androgen receptor inhibitor that increases overall survival in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive and nonmetastatic castration-resistant prostate cancer (PCa). This phase 2 study assessed the efficacy and safety of darolutamide as monotherapy without ADT in patients with eugonadal testosterone levels.

Mots clés

Antiandrogen, Darolutamide, Gonadotropin-releasing hormone analog, Health-related quality of life, Hormone therapy, Prostate cancer

Référence

Eur Urol Oncol. 2024 01 24;: